


Olodanrigan

Chemical Properties

CAS No. :	1316755-16-4
Formula:	C ₃₂ H ₂₉ N ₅ O
Molecular Weight:	507.58
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Olodanrigan (EMA401), a highly selective AT ₂ R antagonist, inhibition of augmented AngII/AT ₂ R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons. EMA401 blocks p38, p42/p44 mitogen-activated protein kinase (MAPK) activation, neurite outgrowth in adult rat DRG neurons, and sensitization of adult rat and human DRG neurons induced by AngII. It inhibits capsaicin responses in cultured hDRG neurons.
Targets(IC50)	RAAS

Solubility Information

Solubility	DMSO: 50 mg/mL (98.51 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Corn Oil: 5 mg/mL (9.85 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9701 mL	9.8507 mL	19.7013 mL
5 mM	0.394 mL	1.9701 mL	3.9403 mL
10 mM	0.197 mL	0.9851 mL	1.9701 mL
50 mM	0.0394 mL	0.197 mL	0.394 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Rice A S C, Dworkin R H, McCarthy T D, et al. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 Clinical trial[J]. *The Lancet*, 2014, 383(9929): 1637-1647.

Anand U, Yiangou Y, Sinisi M, et al. Mechanisms underlying Clinical efficacy of Angiotensin II type 2 receptor (AT 2 R) antagonist EMA401 in neuropathic pain: Clinical tissue and in vitro studies[J]. *Molecular pain*, 2015, 11(1): 38.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481